Natural History of Ocular GVHD

Bishop, Rachel

Abstract

There are no data yet to report on this protocol. To date, ten subjects have been enrolled, with the first participant just reaching the one-year exam following autologous stem cell transplant. Several patients were advised to initiate topical cyclosporine eye drops in response to changes in ocular indicators (symptoms, drop in Schirmers tear production, or worsening of surface dryness). Our team hopes to correlate changes in patient symptoms and exam findings with changes in the tear fluid biomarkers, and expects to have initial results by the next reporting period.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Eye Institute (NEI)
• Type: Investigator-Initiated Intramural Research Projects (ZIA)
• Project #: 1ZIAEY000512-01
• Application #: 8556874
• Support Year: 1
• Fiscal Year: 2012
• Total Cost: $194,807

Institution

• Name: U.S. National Eye Institute

Publications

Brooks, Brian P; Thompson, Amy H; Bishop, Rachel J et al. (2013) Ocular manifestations of xeroderma pigmentosum: long-term follow-up highlights the role of DNA repair in protection from sun damage. Ophthalmology 120:1324-36

Baird, Kristin; Steinberg, Seth M; Grkovic, Lana et al. (2013) National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant 19:632-9

Wang, Yujuan; Marciano, Beatriz E; Shen, Defen et al. (2013) Molecular identification of bacterial DNA in the chorioretinal scars of chronic granulomatous disease. J Clin Immunol 33:917-24

Smith, Wendy M; Reddy, Madhu G; Hutcheson, Kelly A et al. (2012) Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalmic Inflamm Infect 2:149-52

Sibley, Cailin H; Plass, Nikki; Snow, Joseph et al. (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64:2375-86